Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma | Zendy

Steven Attia | Zendy; Scott H. Okuno | Zendy; Steven I. Robinson | Zendy; Nicholas Webber | Zendy; Daniel J. Indelicato | Zendy; Robin L. Jones | Zendy; Sanjay P. Bagaria | Zendy; Courtney E. Sherman | Zendy; Kevin R. Kozak | Zendy; Cherise Cortese | Zendy; Thomas McFarland | Zendy; Jonathan C. Trent | Zendy; Robert G. Maki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma

Author(s) -

Steven Attia,

Scott H. Okuno,

Steven I. Robinson,

Nicholas Webber,

Daniel J. Indelicato,

Robin L. Jones,

Sanjay P. Bagaria,

Courtney E. Sherman,

Kevin R. Kozak,

Cherise Cortese,

Thomas McFarland,

Jonathan C. Trent,

Robert G. Maki

Publication year - 2015

Publication title -

rare tumors

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.285

H-Index - 15

eISSN - 2036-3613

pISSN - 2036-3605

DOI - 10.4081/rt.2015.5992

Subject(s) - pazopanib , medicine , regorafenib , sarcoma , oncology , ewing's sarcoma , liposarcoma , myxoid liposarcoma , cancer research , pathology , cancer , colorectal cancer , sunitinib

We report a response to pazopanib in a 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research